Indegene Limited , a digital-first life sciences commercialization company, has announced its financial results for the first quarter of fiscal year 2026, along with key strategic initiatives aimed at driving future growth.

Financial Highlights

Indegene reported a consolidated revenue of ₹7,608 million for Q1 FY26, representing a 1.8% quarter-on-quarter (QoQ) growth in USD terms and a 12.5% year-on-year (YoY) increase. The company maintained a strong profitability profile with an EBITDA margin of 20.2% and a PAT margin of 15.3%.

Key financial metrics for Q1 FY26:

Segment Performance

Indegene's business segments showed mixed performance:

1. Enterprise Commercial Solutions (ECS): Revenue of ₹4,453 million, up 4.6% QoQ
2. Enterprise Medical Solutions (EMS): Revenue of ₹2,132 million, up 1.2% QoQ
3. Brand Activation: Revenue of ₹758 million, down 21.6% QoQ due to project delays and conclusion of a large project

Strategic Growth Initiatives

Manish Gupta, Chairman and CEO of Indegene, outlined several strategic focus areas for FY26:

1. Tectonic Initiative: This strategic program aims to move Indegene upstream in the marketing value chain for commercial content creation. It has already started generating revenue, contributing over $1 million across two customers in Q1.

2. Sales and Go-to-Market Reorganization: The company has implemented a strategic review of account coverage and remapped its approach to maximize breadth and depth of coverage. Separate teams now focus on large deals and growth accounts.

3. Business Capability Enhancement: Indegene is strengthening its ECS and EMS capabilities by onboarding senior talent in Data & Analytics, Content, Medical Affairs, and Regulatory Affairs.

4. Consulting Practice Repositioning: The consulting practice has been given a broader remit with more strategic involvement in engagements for better client management and change management handling.

5. Operational Excellence: Indegene is implementing the Malcolm Baldrige Model to drive operational excellence across the organization.

6. M&A Focus: The company has identified priority areas for mergers and acquisitions, including Data & Analytics capability enhancement, Medical capability enhancement, and Business IT implementation. A dedicated team of 10 people is involved in M&A efforts.

Management Commentary

Manish Gupta, Chairman and CEO, commented: "We continued our growth momentum in Q1FY26, delivering 1.8% growth QoQ in USD. This reflects a strong start to the year and indicates good traction with our clients and from recent deal wins. This was a good quarter for new pipeline growth, and we maintained the momentum on deal wins as well."

Suhas Prabhu, CFO, added: "In Q1FY26, we maintained our trajectory of stable and profitable growth. Both EBITDA margins and PAT margins were on stable lines, even as we continued investing in scaling Tectonic engagements. We have a strong cash position and balance sheet and remain focused on M&A opportunities."

Industry Recognition

Indegene continues to gain recognition in the industry:

• Named a Leader in Life Sciences AI and Analytics Services by Everest Group
• Identified as a Leader in ISG's Provider Lens™ Evaluation for Life Sciences Digital Services in Commercial Operations
• Recognized as an Innovator in Veeva Services 2025 RadarView™ by Avasant

As Indegene implements its strategic initiatives and focuses on expanding its capabilities, the company aims to strengthen its position in the life sciences commercialization market and drive sustainable growth in the coming quarters.

Indegene Limited , a digital-first life sciences commercialization company, has reported a strong start to the fiscal year with impressive financial results for the first quarter ended June 30.

Financial Highlights

• Revenue from operations increased by 12.5% year-over-year to ₹7,608.00 million
• EBITDA grew by 15.7% to ₹1,536.00 million, with a margin of 20.2%
• Profit after tax surged by 32.7% to ₹1,164.00 million
• Basic earnings per share improved to ₹4.86 from ₹3.79 in the same quarter last year

Segment Performance

Indegene's business segments showed varied performance:

The company's core segments, Enterprise Commercial Solutions and Enterprise Medical Solutions, demonstrated robust growth of 18.8% and 12.8% year-over-year, respectively. However, the Brand Activation segment (formerly known as Omnichannel Activation) experienced a decline of 8.0%.

Strategic Initiatives and Market Recognition

Indegene has made significant strides in its strategic initiatives:

• The company's 'Tectonic' initiative, aimed at moving upstream in the marketing value chain, has started generating revenue.
• Indegene maintained strong client relationships, with 40 clients contributing over $1 million in revenue.
• The company received recognition from industry analysts, including leadership positions in Everest Group's Life Sciences AI and Analytics Services PEAK Matrix® Assessment and ISG's Provider Lens™ for Life Sciences Digital Services in Commercial Operations.

Management Commentary

Manish Gupta, Chairman and CEO of Indegene, stated, "We continued our growth momentum in Q1, delivering 1.8% growth QoQ in USD. This reflects a strong start to the year and indicates good traction with our clients and from recent deal wins."

Suhas Prabhu, CFO, added, "In Q1, we maintained our trajectory of stable and profitable growth. Both EBITDA margins and PAT margins were on stable lines, even as we continued investing in scaling Tectonic engagements."

Additional Information

• The board approved share allotment under the ESOP 2020 Plan.
• A final dividend of ₹2.00 per share was paid for the financial year 2024-25.
• Total comprehensive income reached ₹1,331.00 million compared to ₹869.00 million in the previous year quarter.

Outlook

Indegene remains focused on its growth strategy, including:

• Strengthening capabilities in Enterprise Commercial Solutions and Enterprise Medical Solutions
• Implementing the Malcolm Baldrige Model to drive operational excellence
• Pursuing M&A opportunities in areas such as Data & Analytics and Medical capability enhancement

The company's strong cash position and balance sheet provide a solid foundation for future growth and expansion initiatives.

Indegene continues to leverage its digital-first approach and deep healthcare expertise to serve the world's top 20 biopharma companies, positioning itself for sustained growth in the evolving life sciences commercialization landscape.